A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI (CALM)

NCT01739127 COMPLETED

The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.

Details

Lead sponsor	University of British Columbia
Status	COMPLETED
Enrolment	83
Start date	2012-11
Completion	2016-02

Conditions

• Psychotic Disorders
• Bipolar Disorder
• Metabolic Syndrome X

Interventions

• Aripiprazole
• Risperidone/Quetiapine

Primary outcomes

• Abdominal distribution of visceral fat versus subcutaneous fat — Baseline (within 12 weeks of starting antipsychotic treatment), and 16 weeks later
  Change over time, and between groups, in amounts of visceral and subcutaneous fat as measured by automated segmentation of a magnetic resonance image (MRI).

Countries

Canada